Deborah Dunsire after three years at Lundbeck: "We're coming up to an inflection point in neuroscience"
Before she took on the role, Deborah Dunsire knew perfectly well that drug development within neurology and psychiatry comes with its own unique challenges compared to cancer, an area in which she has spent the majority of her career. Improvements for brain disorders are on the way, but the road ahead is long, says the CEO at Lundbeck.
by ELIZABETH MØNSTED JOHANSEN, translated by Daniel Pedersen
In many ways, it was a journey back in time for Deborah Dunsire when she took the job as CEO at Lundbeck. This is not to say Denmark's life sciences industry is lagging behind the US. Rather, it has something to do specifically with the disease area with which she is now working.
While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.
Epkinly has become the first and only subcutaneously administered T-cell engaging bispecific antibody approved in the US for the treatment of this patient population.
While the findings of a legal investigation were so serious that a Demant executive was fired, the majority owner of the hearing aid company subsequently elected him to several boards.
The success of Novo Nordisk’s Ozempic and Wegovy as well as blockbuster shots made by rival Eli Lilly has left some patients with diabetes struggling to continue their treatment.